Improved prediction of symptomatic type 1 diabetes using a luciferase‐based assay to measure (pro)insulin autoantibodies
Authors' conclusion
The IAA LIPS low-blood-volume, high-throughput technique identifies more individuals with the highest risk of diabetes.
Study context
- Population
- People with new-onset T1D and first-degree relatives (FDRs), of whom 91 developed diabetes during follow-upPeople with new-onset T1D 150 · first-degree relatives (FDRs) 619
- Comparison
- IAA by luciferase immunoprecipitation system (LIPS) vs micro-RBA
- Outcome
- Agreement in IAA status between RBA and LIPS, new-onset diabetes
Methodological detailscross-sectional observational
- Cross-sectional observational
Performance
As reported in the abstract
RBA and LIPS agreement in IAA status in new-onset diabetes
88%
Further findings
High-moderate affinity IAA vs Low-affinity IAA
Positive IAA LIPS by IAA affinity in FDRs
P < 0.001
- Positive IAA LIPS by IAA affinity in FDRs: 89 vs 22 FDRs
IAA LIPS positive vs IAA LIPS negative
20-year diabetes risk in FDRs positive for multiple other islet autoantibodies, by IAA LIPS status
P = 0.013
Independent contribution of IAA LIPS to diabetes risk
- IAA LIPS added to diabetes risk independently of status/level of IAA by RBA, other autoantibodies and sampling age
- P < 0.001
Original publication
Improved prediction of symptomatic type 1 diabetes using a luciferase‐based assay to measure (pro)insulin autoantibodies. Diabet Med. Published 23 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →